Seven Mile Advisory’s AstraZeneca AZN Stock Holding History

Seven Mile Advisory’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$416K	Buy	2,111 +7	+0.3%	+$1.35K	0.3%	70
2025 Q4	$387K	Sell	2,104 -344	-14%	-$60.3K	0.07%	140
2025 Q3	$376K	Buy	2,448 +252	+11%	+$38.1K	0.06%	170
2025 Q2	$307K	Sell	2,196 -84	-4%	-$11.8K	0.18%	116
2025 Q1	$335K	Buy	2,280 +227	+11%	+$32.8K	0.22%	97
2024 Q4	$269K	Sell	2,053 -33	-2%	-$4.62K	0.17%	113
2024 Q3	$325K	Buy	2,086 +375	+22%	+$60.5K	0.22%	93
2024 Q2	$267K	Buy	1,711 +189	+12%	+$28.4K	0.2%	107
2024 Q1	$206K	Buy	+1,522	New	+$202K	0.16%	148
2023 Q4	–	Sell	-1,833	Closed	-$248K	–	152
2023 Q3	$248K	Buy	1,833 +109	+6%	+$14.9K	0.26%	91
2023 Q2	$247K	Buy	+1,724	New	+$254K	0.29%	84

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Seven Mile Advisory's AZN Position: Q1 2026 in Review

Seven Mile Advisory increased its AstraZeneca (AZN) stake by 0.33% in Q1 2026, buying an estimated $1.35K and bringing the position to 2,111 shares worth $416K. The position accounts for 0.3% of the portfolio, ranked #70.

Seven Mile Advisory first reported a position in AZN in Q2 2023 and has held it in 11 quarters since. 1,378 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Seven Mile Advisory held 2,111 shares of AstraZeneca worth $416K as of Q1 2026.
Seven Mile Advisory bought 7 AstraZeneca shares in Q1 2026, an estimated $1.35K.
AstraZeneca made up 0.3% of Seven Mile Advisory's portfolio in Q1 2026, its #70 holding.
Seven Mile Advisory first reported a position in AstraZeneca in Q2 2023 and has held it in 11 quarters since.
1,378 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Seven Mile Advisory's 13F filing for Q1 2026, filed 14 Apr 2026.